All posts from Zacks
Zacks in Our Research. Your Success.,

Insulet (PODD) Shows Strength: Stock Adds 7.1% in Session

Insulet Corporation PODD was a big mover last session, as its shares rose over 7% on the day. The move came on the back of revenue growth and raised 2017 guidance in second-quarter 2017 results. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range $49.49 to $53.52 in the past one-month time frame.

Over the last 30 days, the company witnessed one negative estimate revision. However, the Zacks Consensus Estimate remained unchanged over the same time frame. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Insulet currently carries a Zacks Rank #3 (Hold).

A better-ranked stock in the Medical – Products space is INSYS Therapeutics, Inc. INSY, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is PODD going up? Or down? Predict to see what others think: Up or Down

5 Trades Could Profit "Big-League" from Trump Policies 

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Insys Therapeutics, Inc. (INSY): Free Stock Analysis Report
Insulet Corporation (PODD): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research